CN112218957A - 用于确定在无细胞核酸中的肿瘤分数的系统及方法 - Google Patents
用于确定在无细胞核酸中的肿瘤分数的系统及方法 Download PDFInfo
- Publication number
- CN112218957A CN112218957A CN201980037052.7A CN201980037052A CN112218957A CN 112218957 A CN112218957 A CN 112218957A CN 201980037052 A CN201980037052 A CN 201980037052A CN 112218957 A CN112218957 A CN 112218957A
- Authority
- CN
- China
- Prior art keywords
- cancer
- variant
- variants
- subject
- sequence reads
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 515
- 238000000034 method Methods 0.000 title claims abstract description 289
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 235
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 198
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 198
- 239000012472 biological sample Substances 0.000 claims abstract description 233
- 230000002159 abnormal effect Effects 0.000 claims abstract description 174
- 239000000523 sample Substances 0.000 claims abstract description 144
- 239000007788 liquid Substances 0.000 claims abstract description 77
- 239000007787 solid Substances 0.000 claims abstract description 47
- 210000001519 tissue Anatomy 0.000 claims description 272
- 201000011510 cancer Diseases 0.000 claims description 251
- 206010006187 Breast cancer Diseases 0.000 claims description 70
- 208000026310 Breast neoplasm Diseases 0.000 claims description 70
- 210000004369 blood Anatomy 0.000 claims description 69
- 239000008280 blood Substances 0.000 claims description 69
- 238000007069 methylation reaction Methods 0.000 claims description 67
- 230000007614 genetic variation Effects 0.000 claims description 62
- 230000011987 methylation Effects 0.000 claims description 61
- 239000002773 nucleotide Substances 0.000 claims description 58
- 125000003729 nucleotide group Chemical group 0.000 claims description 57
- 108700028369 Alleles Proteins 0.000 claims description 46
- 201000001441 melanoma Diseases 0.000 claims description 45
- 206010005003 Bladder cancer Diseases 0.000 claims description 43
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 43
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 43
- 201000002510 thyroid cancer Diseases 0.000 claims description 43
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 43
- 208000034578 Multiple myelomas Diseases 0.000 claims description 42
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 42
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 42
- 206010017758 gastric cancer Diseases 0.000 claims description 42
- 201000011549 stomach cancer Diseases 0.000 claims description 42
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 41
- 206010025323 Lymphomas Diseases 0.000 claims description 41
- 206010038389 Renal cancer Diseases 0.000 claims description 41
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 41
- 201000010881 cervical cancer Diseases 0.000 claims description 41
- 201000010982 kidney cancer Diseases 0.000 claims description 41
- 208000032839 leukemia Diseases 0.000 claims description 41
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 40
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 40
- 230000006870 function Effects 0.000 claims description 40
- 201000005202 lung cancer Diseases 0.000 claims description 40
- 208000020816 lung neoplasm Diseases 0.000 claims description 40
- 210000004027 cell Anatomy 0.000 claims description 39
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 39
- 210000002381 plasma Anatomy 0.000 claims description 39
- 206010009944 Colon cancer Diseases 0.000 claims description 38
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 38
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 38
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 38
- 206010033128 Ovarian cancer Diseases 0.000 claims description 38
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 38
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 38
- 201000004101 esophageal cancer Diseases 0.000 claims description 38
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 38
- 201000002528 pancreatic cancer Diseases 0.000 claims description 38
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 38
- 206010060862 Prostate cancer Diseases 0.000 claims description 37
- 230000035772 mutation Effects 0.000 claims description 37
- 206010046766 uterine cancer Diseases 0.000 claims description 37
- 241000282414 Homo sapiens Species 0.000 claims description 36
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 36
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 36
- 201000010536 head and neck cancer Diseases 0.000 claims description 34
- 230000001186 cumulative effect Effects 0.000 claims description 33
- 210000004185 liver Anatomy 0.000 claims description 26
- 210000003296 saliva Anatomy 0.000 claims description 24
- 210000002966 serum Anatomy 0.000 claims description 24
- 210000002700 urine Anatomy 0.000 claims description 24
- 208000005228 Pericardial Effusion Diseases 0.000 claims description 23
- 210000003567 ascitic fluid Anatomy 0.000 claims description 23
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 23
- 238000003780 insertion Methods 0.000 claims description 23
- 230000037431 insertion Effects 0.000 claims description 23
- 210000004912 pericardial fluid Anatomy 0.000 claims description 23
- 210000004910 pleural fluid Anatomy 0.000 claims description 23
- 210000004243 sweat Anatomy 0.000 claims description 23
- 210000001138 tear Anatomy 0.000 claims description 23
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 20
- 238000005315 distribution function Methods 0.000 claims description 20
- 201000010175 gallbladder cancer Diseases 0.000 claims description 20
- 201000007270 liver cancer Diseases 0.000 claims description 19
- 208000014018 liver neoplasm Diseases 0.000 claims description 19
- 230000008859 change Effects 0.000 claims description 17
- 230000001594 aberrant effect Effects 0.000 claims description 16
- 238000003745 diagnosis Methods 0.000 claims description 16
- 238000003860 storage Methods 0.000 claims description 16
- 238000012217 deletion Methods 0.000 claims description 15
- 230000037430 deletion Effects 0.000 claims description 15
- 238000009826 distribution Methods 0.000 claims description 14
- 208000003837 Second Primary Neoplasms Diseases 0.000 claims description 13
- 238000012706 support-vector machine Methods 0.000 claims description 13
- 210000000481 breast Anatomy 0.000 claims description 12
- 210000004072 lung Anatomy 0.000 claims description 11
- 238000013528 artificial neural network Methods 0.000 claims description 10
- 238000003066 decision tree Methods 0.000 claims description 10
- 230000007423 decrease Effects 0.000 claims description 10
- 230000006798 recombination Effects 0.000 claims description 10
- 238000005215 recombination Methods 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 210000003734 kidney Anatomy 0.000 claims description 9
- 210000003128 head Anatomy 0.000 claims description 8
- 210000003739 neck Anatomy 0.000 claims description 8
- 210000002307 prostate Anatomy 0.000 claims description 8
- 210000001685 thyroid gland Anatomy 0.000 claims description 8
- 210000003932 urinary bladder Anatomy 0.000 claims description 8
- 230000004075 alteration Effects 0.000 claims description 7
- 210000003679 cervix uteri Anatomy 0.000 claims description 6
- 210000003238 esophagus Anatomy 0.000 claims description 6
- 210000000232 gallbladder Anatomy 0.000 claims description 6
- 210000001672 ovary Anatomy 0.000 claims description 6
- 210000000496 pancreas Anatomy 0.000 claims description 6
- 210000004291 uterus Anatomy 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 5
- 238000004393 prognosis Methods 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 description 128
- 230000000875 corresponding effect Effects 0.000 description 99
- 238000012163 sequencing technique Methods 0.000 description 90
- 239000012634 fragment Substances 0.000 description 59
- 238000004458 analytical method Methods 0.000 description 36
- 238000003556 assay Methods 0.000 description 35
- 238000012549 training Methods 0.000 description 30
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 28
- 108091029430 CpG site Proteins 0.000 description 27
- 210000000265 leukocyte Anatomy 0.000 description 25
- 201000010099 disease Diseases 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 18
- 238000001514 detection method Methods 0.000 description 18
- 238000009396 hybridization Methods 0.000 description 18
- 238000012070 whole genome sequencing analysis Methods 0.000 description 18
- 206010073073 Hepatobiliary cancer Diseases 0.000 description 16
- 230000000392 somatic effect Effects 0.000 description 16
- 210000000349 chromosome Anatomy 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 230000008569 process Effects 0.000 description 14
- 238000005259 measurement Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 238000004422 calculation algorithm Methods 0.000 description 12
- 230000002085 persistent effect Effects 0.000 description 12
- 238000001369 bisulfite sequencing Methods 0.000 description 11
- 229940104302 cytosine Drugs 0.000 description 11
- 230000035945 sensitivity Effects 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 238000010586 diagram Methods 0.000 description 9
- 238000007481 next generation sequencing Methods 0.000 description 9
- 229940035893 uracil Drugs 0.000 description 9
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 8
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 108091092584 GDNA Proteins 0.000 description 7
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 238000002790 cross-validation Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000013507 mapping Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 238000004891 communication Methods 0.000 description 5
- 238000007477 logistic regression Methods 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 238000005192 partition Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 206010069754 Acquired gene mutation Diseases 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 4
- 208000003174 Brain Neoplasms Diseases 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 102000019040 Nuclear Antigens Human genes 0.000 description 4
- 108010051791 Nuclear Antigens Proteins 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 description 4
- 230000001143 conditioned effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000037439 somatic mutation Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 206010061252 Intraocular melanoma Diseases 0.000 description 3
- 206010025537 Malignant anorectal neoplasms Diseases 0.000 description 3
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- 201000005969 Uveal melanoma Diseases 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000007621 cluster analysis Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000007672 fourth generation sequencing Methods 0.000 description 3
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 230000000869 mutational effect Effects 0.000 description 3
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 3
- 201000002575 ocular melanoma Diseases 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 201000002523 pancreas lymphoma Diseases 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 238000007637 random forest analysis Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 2
- 235000002198 Annona diversifolia Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000283153 Cetacea Species 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
- 241000282575 Gorilla Species 0.000 description 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 108010047956 Nucleosomes Proteins 0.000 description 2
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 241000282849 Ruminantia Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000283907 Tragelaphus oryx Species 0.000 description 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 2
- 241001416177 Vicugna pacos Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 238000011256 aggressive treatment Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 208000026900 bile duct neoplasm Diseases 0.000 description 2
- 210000003445 biliary tract Anatomy 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 230000004049 epigenetic modification Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000006607 hypermethylation Effects 0.000 description 2
- 238000003064 k means clustering Methods 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000001623 nucleosome Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 208000007312 paraganglioma Diseases 0.000 description 2
- 210000003695 paranasal sinus Anatomy 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000013139 quantization Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000007430 reference method Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000011524 similarity measure Methods 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000008261 skin carcinoma Diseases 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 208000001608 teratocarcinoma Diseases 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 208000037965 uterine sarcoma Diseases 0.000 description 2
- 206010046885 vaginal cancer Diseases 0.000 description 2
- 208000013139 vaginal neoplasm Diseases 0.000 description 2
- 238000007482 whole exome sequencing Methods 0.000 description 2
- CJYDNDLQIIGSTH-UHFFFAOYSA-N 1-(3,5,7-trinitro-1,3,5,7-tetrazocan-1-yl)ethanone Chemical compound CC(=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)CN([N+]([O-])=O)C1 CJYDNDLQIIGSTH-UHFFFAOYSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 description 1
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010073360 Appendix cancer Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 206010006200 Breast cancer stage II Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 101100129500 Caenorhabditis elegans max-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241001481833 Coryphaena hippurus Species 0.000 description 1
- 241001125840 Coryphaenidae Species 0.000 description 1
- 108091029523 CpG island Proteins 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000030933 DNA methylation on cytosine Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 241000282323 Felidae Species 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 208000017263 Gonadal germ cell tumor Diseases 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 102000009875 Ki-67 Antigen Human genes 0.000 description 1
- 108010020437 Ki-67 Antigen Proteins 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000282842 Lama glama Species 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000005927 Myosarcoma Diseases 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 1
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 208000000160 Olfactory Esthesioneuroblastoma Diseases 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010067517 Pancreatic neuroendocrine tumour Diseases 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 201000002454 adrenal cortex cancer Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- 238000013398 bayesian method Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000008873 bone osteosarcoma Diseases 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000019772 childhood adrenal gland pheochromocytoma Diseases 0.000 description 1
- 208000023973 childhood bladder carcinoma Diseases 0.000 description 1
- 208000026046 childhood carcinoid tumor Diseases 0.000 description 1
- 208000015632 childhood ependymoma Diseases 0.000 description 1
- 208000028190 childhood germ cell tumor Diseases 0.000 description 1
- 208000013549 childhood kidney neoplasm Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012350 deep sequencing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- -1 e.g. Proteins 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000023965 endometrium neoplasm Diseases 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 208000013010 hypopharyngeal carcinoma Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 201000002529 islet cell tumor Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 238000011545 laboratory measurement Methods 0.000 description 1
- 238000012177 large-scale sequencing Methods 0.000 description 1
- 201000005264 laryngeal carcinoma Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 201000003175 male breast cancer Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 238000012164 methylation sequencing Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 201000002077 muscle cancer Diseases 0.000 description 1
- 201000006462 myelodysplastic/myeloproliferative neoplasm Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 201000008859 olfactory neuroblastoma Diseases 0.000 description 1
- 208000020668 oropharyngeal carcinoma Diseases 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 208000021010 pancreatic neuroendocrine tumor Diseases 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 201000000389 pediatric ependymoma Diseases 0.000 description 1
- 201000002524 peritoneal carcinoma Diseases 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000013138 pruning Methods 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 208000010639 renal pelvis urothelial carcinoma Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000020352 skin basal cell carcinoma Diseases 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004291 sulphur dioxide Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000018417 undifferentiated high grade pleomorphic sarcoma of bone Diseases 0.000 description 1
- 201000000334 ureter transitional cell carcinoma Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
- G06N20/00—Machine learning
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/30—Unsupervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Theoretical Computer Science (AREA)
- Data Mining & Analysis (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Software Systems (AREA)
- Analytical Chemistry (AREA)
- Evolutionary Computation (AREA)
- Databases & Information Systems (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Artificial Intelligence (AREA)
- Genetics & Genomics (AREA)
- Bioethics (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Primary Health Care (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Computing Systems (AREA)
- General Physics & Mathematics (AREA)
- Mathematical Physics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
Abstract
Description
Claims (112)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862658479P | 2018-04-16 | 2018-04-16 | |
US62/658,479 | 2018-04-16 | ||
PCT/US2019/027756 WO2019204360A1 (en) | 2018-04-16 | 2019-04-16 | Systems and methods for determining tumor fraction in cell-free nucleic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112218957A true CN112218957A (zh) | 2021-01-12 |
Family
ID=68240325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980037052.7A Pending CN112218957A (zh) | 2018-04-16 | 2019-04-16 | 用于确定在无细胞核酸中的肿瘤分数的系统及方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20210104297A1 (zh) |
EP (1) | EP3781709A4 (zh) |
CN (1) | CN112218957A (zh) |
WO (1) | WO2019204360A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023115662A1 (zh) * | 2021-12-24 | 2023-06-29 | 广州燃石医学检验所有限公司 | 一种变体核酸的检测方法 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210285042A1 (en) | 2020-02-28 | 2021-09-16 | Grail, Inc. | Systems and methods for calling variants using methylation sequencing data |
US20210292845A1 (en) | 2020-02-28 | 2021-09-23 | Grail, Inc. | Identifying methylation patterns that discriminate or indicate a cancer condition |
CN115702457A (zh) * | 2020-03-04 | 2023-02-14 | 格里尔公司 | 使用自动编码器确定癌症状态的系统和方法 |
CA3202038A1 (en) * | 2020-12-18 | 2022-06-23 | George Koumbaris | Methods for classifying a sample into clinically relevant categories |
CA3227495A1 (en) | 2021-08-05 | 2023-02-09 | Grail, Inc. | Somatic variant cooccurrence with abnormally methylated fragments |
EP4138003A1 (en) * | 2021-08-20 | 2023-02-22 | Dassault Systèmes | Neural network for variant calling |
US20240021267A1 (en) * | 2022-07-18 | 2024-01-18 | Grail, Llc | Dynamically selecting sequencing subregions for cancer classification |
WO2024050242A1 (en) * | 2022-08-29 | 2024-03-07 | Foundation Medicine, Inc. | Methods and systems for detecting tumor shedding |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110212855A1 (en) * | 2008-08-15 | 2011-09-01 | Decode Genetics Ehf. | Genetic Variants Predictive of Cancer Risk |
US11261494B2 (en) * | 2012-06-21 | 2022-03-01 | The Chinese University Of Hong Kong | Method of measuring a fractional concentration of tumor DNA |
GB201412834D0 (en) * | 2014-07-18 | 2014-09-03 | Cancer Rec Tech Ltd | A method for detecting a genetic variant |
US10125399B2 (en) * | 2014-10-30 | 2018-11-13 | Personalis, Inc. | Methods for using mosaicism in nucleic acids sampled distal to their origin |
CN113930507A (zh) * | 2014-12-31 | 2022-01-14 | 夸登特健康公司 | 疾病的检测和治疗以及用于传送测试结果的系统和方法 |
WO2016127944A1 (en) * | 2015-02-10 | 2016-08-18 | The Chinese University Of Hong Kong | Detecting mutations for cancer screening and fetal analysis |
EP3464626B1 (en) * | 2016-05-27 | 2022-04-06 | Sequenom, Inc. | Methods for detecting genetic variations |
-
2019
- 2019-04-16 WO PCT/US2019/027756 patent/WO2019204360A1/en unknown
- 2019-04-16 US US17/047,676 patent/US20210104297A1/en active Pending
- 2019-04-16 EP EP19788160.0A patent/EP3781709A4/en active Pending
- 2019-04-16 CN CN201980037052.7A patent/CN112218957A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023115662A1 (zh) * | 2021-12-24 | 2023-06-29 | 广州燃石医学检验所有限公司 | 一种变体核酸的检测方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2019204360A1 (en) | 2019-10-24 |
EP3781709A4 (en) | 2022-11-30 |
US20210104297A1 (en) | 2021-04-08 |
EP3781709A1 (en) | 2021-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI822789B (zh) | 用於資料分類之卷積神經網路系統及方法 | |
CN112218957A (zh) | 用于确定在无细胞核酸中的肿瘤分数的系统及方法 | |
TWI814753B (zh) | 用於標靶定序之模型 | |
CA3129831A1 (en) | An integrated machine-learning framework to estimate homologous recombination deficiency | |
US11869661B2 (en) | Systems and methods for determining whether a subject has a cancer condition using transfer learning | |
US20210065842A1 (en) | Systems and methods for determining tumor fraction | |
CN112602156A (zh) | 用于检测残留疾病的系统和方法 | |
US11581062B2 (en) | Systems and methods for classifying patients with respect to multiple cancer classes | |
US20200219587A1 (en) | Systems and methods for using fragment lengths as a predictor of cancer | |
US20200340064A1 (en) | Systems and methods for tumor fraction estimation from small variants | |
US20210358626A1 (en) | Systems and methods for cancer condition determination using autoencoders | |
US20210102262A1 (en) | Systems and methods for diagnosing a disease condition using on-target and off-target sequencing data | |
CN113661542A (zh) | 使用甲基化信息估计细胞来源部分的系统和方法 | |
CN115461472A (zh) | 使用合成添加训练样品进行癌症分类 | |
US20220090211A1 (en) | Sample Validation for Cancer Classification | |
CN115956132A (zh) | 人乳头瘤病毒相关癌症的检测及分类 | |
CN115244622A (zh) | 使用甲基化测序数据调用变体的系统和方法 | |
JP2023514851A (ja) | 癌の病態を判別または示すメチル化パターンの同定 | |
US20240021267A1 (en) | Dynamically selecting sequencing subregions for cancer classification | |
US20240170099A1 (en) | Methylation-based age prediction as feature for cancer classification |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40040539 Country of ref document: HK |
|
CB02 | Change of applicant information |
Address after: Menlo Park, California, USA Applicant after: GRAIL, Inc. Address before: Menlo Park, California, USA Applicant before: SDG OPS Ltd. |
|
CB02 | Change of applicant information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220418 Address after: Menlo Park, California, USA Applicant after: SDG OPS Ltd. Address before: Menlo Park, California, USA Applicant before: GRAIL, Inc. |
|
TA01 | Transfer of patent application right |